International Cooperation on Harmonisation of Technical Requirements for Registration of Veterinary Medicinal Products; Effectiveness of Anthelmintics: Specific Recommendations for Canines; Guidance for Industry; Availability
FDA announces availability of a guidance on effectiveness recommendations for anthelmintics in canines, aligning with international harmonization efforts. No immediate regulatory changes for manufacturers.
Aforeworn detected this change in the Pharmaceutical Manufacturing (FDA/DEA) space on July 16, 2026 and published this briefing so affected operators are forewarned rather than caught off guard. It is rated Low urgency. Veterinary pharmaceutical manufacturers, especially those producing anthelmintics for canines should confirm how it applies to their specific situation before acting. There is a time constraint attached: None; guidance is effective immediately but non-binding. Acting after that point can mean penalties, a lapsed licence, or lost eligibility — exactly the kind of surprise Aforeworn exists to prevent. Aforeworn monitors Pharmaceutical Manufacturing (FDA/DEA) continuously and turns every detected change into a plain-English briefing like this one, so you always know first. Forewarned is forearmed.
What changed
New FDA guidance providing specific recommendations for demonstrating effectiveness of anthelmintics in canines, part of international harmonization
Who it affects
Veterinary pharmaceutical manufacturers, especially those producing anthelmintics for canines
What you must do
Review guidance for potential updates to study designs or data requirements; no immediate action required
Deadline
None; guidance is effective immediately but non-binding
Never miss a change like this again
Aforeworn watches Pharmaceutical Manufacturing (FDA/DEA) around the clock and alerts you the moment a rule moves — with a plain-English brief on what to do.
Start your free trialRelated changes in Pharmaceutical Manufacturing (FDA/DEA)
- IL HB0004: MEDICAID-PHARMACY SERVICES
- Drugs for Human Use; Drug Efficacy Study Implementation: Estrogen-Androgen Fixed-Combination Drug Products; Extension of Effective Date of Final Resolution of Drug Efficacy Study Implementation 7661
- Determination That RECTIV (Nitroglycerin) Ointment, 0.4%, Was Not Withdrawn From Sale for Reasons of Safety or Effectiveness
- Determination That Prednisolone Tablet, 5 Milligrams, Was Not Withdrawn From Sale for Reasons of Safety or Effectiveness
- Determination That VASOPRESSIN IN SODIUM CHLORIDE (vasopressin) 0.9%, Injection, 50 units/50 milliliters (1 unit/milliliters) Was Not Withdrawn From Sale for Reasons of Safety or Effectiveness